Director at Oncolytics Biotech (NASDAQ: ONCY) acquires 100,000 common shares

Rhea-AI Filing Summary

Oncolytics Biotech Inc. director Bernd R. Seizinger reported buying additional common shares of the company. On January 16, 2026, he acquired 100,000 common shares of Oncolytics Biotech at a weighted average price of $1.0377 per share, through multiple trades executed between $1.0294 and $1.0499.

Following this purchase, Seizinger beneficially owns 466,991 common shares, held directly. The filing notes that full detail on the number of shares bought at each individual price within the stated range is available upon request from the company, any security holder, or the SEC staff.

Insider Trade Summary

Net Buyer: 100,000 shares ($103,770)

Net Buy 1 txn

Insider Seizinger Bernd R.

Role Director

Bought 100,000 shs ($104K)

Type	Security	Shares	Price	Value
Purchase	Common Shares	100,000	$1.0377	$104K

Holdings After Transaction: Common Shares — 466,991 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Seizinger Bernd R.

(Last) (First) (Middle)

C/O ONCOLYTICS BIOTECH INC.

4350 EXECUTIVE DRIVE, SUITE 325

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ONCOLYTICS BIOTECH INC [ ONCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	01/16/2026		P		100,000	A	$1.0377(1)	466,991	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.0294 to $1.0499, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

	/s/ Kirk Look, Attorney-in-Fact	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ONCY disclose in this Form 4?

The filing shows that director Bernd R. Seizinger purchased 100,000 common shares of Oncolytics Biotech Inc. on January 16, 2026.

At what price did the ONCY director acquire the shares?

The weighted average purchase price for the 100,000 common shares was $1.0377 per share, with individual trades between $1.0294 and $1.0499.

How many Oncolytics Biotech (ONCY) shares does the insider own after this trade?

After the reported purchase, Bernd R. Seizinger beneficially owns 466,991 common shares of Oncolytics Biotech Inc., held directly.

What does the weighted average price disclosure mean in the ONCY Form 4?

It means the $1.0377 price represents a weighted average across multiple trades between $1.0294 and $1.0499; detailed trade-by-trade pricing is available on request.

What is the role of the reporting person in Oncolytics Biotech (ONCY)?

The reporting person, Bernd R. Seizinger, is identified in the filing as a director of Oncolytics Biotech Inc.

Is the ONCY insider transaction reported as direct or indirect ownership?

The 466,991 common shares reported after the transaction are shown as held with direct ownership.